Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively...
EuroPCR -- Keystone Heart has announced that a pooled analysis of three prospective and comparable clinical studies of patients undergoing TAVR in US and Europe, further corroborates that TriGuard™...
Resources will be channeled towards randomized clinical studies and further commercialization. Keystone Heart will exhibit and present at EuroPCR next week in Paris. CAESAREA, Israel, May 15, 2014...
CE Marking for the TriGuard™ device, devised to minimize the risk of brain damage during TAVR, enables commencement of commercial use Recent data demonstrates considerable reduction of new brain...
New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.